Suppr超能文献

血浆氨水平可预测肝硬化临床稳定门诊患者的肝相关并发症和死亡率。

Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.

机构信息

Institute of Liver Studies, Dept of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Digestive Disease Department, Hospital Clínico Universitario de Valencia, Spain; INCLIVA Biomedical Research Institute, Valencia, Spain.

出版信息

J Hepatol. 2022 Dec;77(6):1554-1563. doi: 10.1016/j.jhep.2022.07.014. Epub 2022 Jul 22.

Abstract

BACKGROUND & AIMS: Hyperammonaemia is central in the pathogenesis of hepatic encephalopathy. It also has pleiotropic deleterious effects on several organ systems, such as immune function, sarcopenia, energy metabolism and portal hypertension. This study was performed to test the hypothesis that severity of hyperammonaemia is a risk factor for liver-related complications in clinically stable outpatients with cirrhosis.

METHODS

We studied 754 clinically stable outpatients with cirrhosis from 3 independent liver units. Baseline ammonia levels were corrected to the upper limit of normal (AMM-ULN) for the reference laboratory. The primary endpoint was hospitalisation with liver-related complications (a composite endpoint of bacterial infection, variceal bleeding, overt hepatic encephalopathy, or new onset or worsening of ascites). Multivariable competing risk frailty analyses using fast unified random forests were performed to predict complications and mortality. External validation was carried out using prospective data from 130 patients with cirrhosis in an independent tertiary liver centre.

RESULTS

Overall, 260 (35%) patients were hospitalised with liver-related complications. On multivariable analysis, AMM-ULN was an independent predictor of both liver-related complications (hazard ratio 2.13; 95% CI 1.89-2.40; p <0.001) and mortality (hazard ratio 1.45; 95% CI 1.20-1.76; p <0.001). The AUROC of AMM-ULN was 77.9% for 1-year liver-related complications, which is higher than traditional severity scores. Statistical differences in survival were found between high and low levels of AMM-ULN both for complications and mortality (p <0.001) using 1.4 as the optimal cut-off from the training set. AMM-ULN remained a key variable for the prediction of complications within the random forests model in the derivation cohort and upon external validation.

CONCLUSION

Ammonia is an independent predictor of hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis and performs better than traditional prognostic scores in predicting complications.

LAY SUMMARY

We conducted a prospective cohort study evaluating the association of blood ammonia levels with the risk of adverse outcomes in 754 patients with stable cirrhosis across 3 independent liver units. We found that ammonia is a key determinant that helps to predict which patients will be hospitalised, develop liver-related complications and die; this was confirmed in an independent cohort of patients.

摘要

背景与目的

高血氨在肝性脑病的发病机制中起核心作用。它对多个器官系统也有多种有害影响,如免疫功能、肌肉减少症、能量代谢和门脉高压。本研究旨在验证这样一个假设,即高血氨的严重程度是临床稳定的肝硬化门诊患者发生肝脏相关并发症的危险因素。

方法

我们研究了来自 3 个独立肝脏单位的 754 例临床稳定的肝硬化门诊患者。将基础血氨水平校正为参考实验室的上限(AMM-ULN)。主要终点是发生与肝脏相关的并发症(细菌感染、静脉曲张出血、显性肝性脑病、新出现或恶化的腹水的复合终点)的住院治疗。使用快速统一随机森林进行多变量竞争风险脆弱性分析,以预测并发症和死亡率。使用来自独立的三级肝脏中心的 130 例肝硬化患者的前瞻性数据进行外部验证。

结果

总体而言,260 例(35%)患者因与肝脏相关的并发症住院。多变量分析显示,AMM-ULN 是与肝脏相关并发症(风险比 2.13;95%CI 1.89-2.40;p<0.001)和死亡率(风险比 1.45;95%CI 1.20-1.76;p<0.001)独立相关的因素。AMM-ULN 对 1 年肝脏相关并发症的 AUROC 为 77.9%,高于传统严重程度评分。在训练集中使用 1.4 作为最佳截断值,在统计学上发现高和低 AMM-ULN 水平之间在并发症和死亡率方面存在差异(p<0.001)。在推导队列和外部验证中,AMM-ULN 仍然是随机森林模型中预测并发症的关键变量。

结论

氨是临床稳定的肝硬化门诊患者住院治疗、发生肝脏相关并发症和死亡的独立预测因子,在预测并发症方面优于传统预后评分。

平铺直叙

我们进行了一项前瞻性队列研究,评估了 3 个独立肝脏单位的 754 例稳定肝硬化患者的血液氨水平与不良结局风险的关联。我们发现,氨是一个关键决定因素,可以帮助预测哪些患者会住院、发生与肝脏相关的并发症和死亡;这在一个独立的患者队列中得到了证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验